Pituitary tumor transforming gene 1 promotes proliferation and malignant phenotype in osteosarcoma via NF-κB signaling

Published:November 19, 2022DOI:


      • PTTG1 is upregulated in osteosarcoma and is associated with poor prognosis.
      • Knockdown of PTTG1 inhibits tumorgenesis of osteosarcoma cells both in vitro and in vivo.
      • PTTG1-knockdown suppresses the NF-κB signaling pathway.



      Pituitary tumor transforming gene (PTTG) is an oncogene reported to be actively promotes tumorigenesis in multiple tumors. Osteosarcoma (OS) is the most common primary osseous sarcoma, however, the functional significance and mechanisms underlying whether and how PTTG1 promotes OS remain largely unknown.


      Here, in our study, PTTG1 levels in clinical samples and cell lines were determined by western blotting and immunohistochemistry. The viability and migratory/invasive potential of OS cells were assessed using Cell Counting Kit-8, colony formation, wound healing, and Transwell assays. The effects of PTTG1 on NF-κB signaling pathways were evaluated both in vivo and in vitro.


      An abnormally elevated expression of PTTG1was confirmed in human OS tissues and OS cell lines and PTTG1 levels were positively correlated with OS clinicopathological grade. We further showed that knocking down PTTG1 attenuated the viability and migratory/invasive capacity of OS cells (MG63 and HOS-8603). Additionally, the following key mechanistic principle was revealed: knockdown PTTG1-mediated OS tumorgenesis supression was associated with inactivation of the NF-κB pathway. We confirmed these results by additional nonpharmacological intervention and same conclusions were obtained in the context of opposite functional analyses. Furthermore, we also demonstrated that OS cell lines overexpressed PTTG1 showed increased tumorigenesis in athymic nude mice.


      To sum up, the present study suggests that PTTG1 is involved in the enhancement of the malignancy and carcinogenesis of OS by regulating NF-κB signaling. Accordingly, PTTG1 likely functions as an oncogene in OS and may represent a potential therapeutic target for this cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Orthopaedic Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Belayneh R.
        • Fourman M.S.
        Update on Osteosarcoma. 2021 Apr 21; 23: 71
        • Jafari F.
        • Javdansirat S.
        • Sanaie S.
        • Naseri A.
        • Shamekh A.
        • Rostamzadeh D.
        • et al.
        Osteosarcoma: a comprehensive review of management and treatment strategies.
        Ann Diagn Pathol. 2020 Dec; 49151654
        • Cersosimo F.
        • Lonardi S.
        • Bernardini G.
        Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy.
        Int J Mol Sci. 2020 Jul 23; 21
        • Wang Y.
        • Tian X.
        • Zhang W.
        • Zhang Z.
        • Lazcano R.
        • Hingorani P.
        • et al.
        Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma.
        Mol Cancer Therapeut. 2022 Jun 1; 21: 903-913
        • Wang C.
        • Yin Q.
        • Liao J.
        • Lou J.
        • Ding X.
        • Zhu Y.
        • et al.
        Primary diaphyseal osteosarcoma in long bones: imaging features and tumor characteristics.
        Eur J Radiol. 2012 Nov; 81: 3397-3403
        • Iwata S.
        • Nakamura T.
        • Gaston C.
        • Carter S.
        • Tillman R.
        • Abudu A.
        • et al.
        Diaphyseal osteosarcomas have distinct clinical features from metaphyseal osteosarcomas.
        Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014 Sep; 40: 1095-1100
        • Lu S.
        • Wang Y.
        • Liu G.
        • Wang L.
        • Wu P.
        • Li Y.
        • et al.
        Construction and validation of nomogram to predict distant metastasis in osteosarcoma: a retrospective study.
        J Orthop Surg Res. 2021 Mar 30; 16: 231
        • Yang C.
        • Tian Y.
        • Zhao F.
        • Chen Z.
        • Su P.
        • Li Y.
        • et al.
        Bone microenvironment and osteosarcoma metastasis.
        Int J Mol Sci. 2020 Sep 23; 21: 6985
        • Dean D.
        • Shen S.
        • Hornicek F.
        • Duan Z.
        From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.
        Cancer Metastasis Rev. 2018 Dec; 37: 719-731
        • Ahmed G.
        • Zamzam M.
        • Kamel A.
        • Ahmed S.
        • Salama A.
        • Zaki I.
        • et al.
        Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients.
        J Pediatr Surg. 2019 Apr; 54: 775-779
        • Wu C.
        • Ekanem T.
        • Phan N.
        • Loan D.
        • Hou S.
        • Lee K.
        • et al.
        Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.
        Int J Med Sci. 2020 Oct 22; 17: 3112-3124
        • Salehi F.
        • Kovacs K.
        • Scheithauer B.
        • Lloyd R.
        • Cusimano M.
        Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.
        Endocr Relat Cancer. 2008 Sep; 15: 721-743
        • Yu R.
        • Melmed S.
        Pituitary tumor transforming gene: an update.
        Front Horm Res. 2008 Sep; 32: 175-185
        • Sáez C.
        • Japón M.
        • Ramos-Morales F.
        • Romero F.
        • Segura D.
        • Tortolero M.
        • et al.
        Hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.
        Oncogene. 1999 Sep 23; 18: 5473-5476
        • Tang Z.
        • Wang P.
        • Chang P.
        • Hasahya T.
        • Xing H.
        • Wang J.
        • et al.
        Association between rs2431697 T allele on 5q33.3 and systemic lupus erythematosus: case-control study and meta-analysis.
        Clin Rheumatol. 2015 Nov; 34: 1893-1902
        • Tong Y.
        • Eigler T.
        Transcriptional targets for pituitary tumor-transforming gene-1.
        J Mol Endocrinol. 2009 Nov; 43: 179-185
        • Vlotides G.
        • Eigler T.
        • Melmed S.
        Pituitary tumor-transforming gene: physiology and implications for tumorigenesis.
        Endocr Rev. 2007 Apr; 28: 165-186
        • Smith V.
        • Franklyn J.
        • McCabe C.
        Pituitary tumor-transforming gene and its binding factor in endocrine cancer.
        Expet Rev Mol Med. 2010 Dec 3; 12: e38
        • Leidecker O.
        • Bonfiglio J.
        • Colby T.
        • Zhang Q.
        • Atanassov I.
        • Zaja R.
        • et al.
        Serine is a new target residue for endogenous ADP-ribosylation on histones.
        Nat Chem Biol. 2016 Dec; 12: 998-1000
        • Matyskiela M.
        • Couto S.
        • Zheng X.
        • Lu G.
        • Hui J.
        • Stamp K.
        • et al.
        SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate.
        Nat Chem Biol. 2018 Oct; 14: 981-987
        • Cui L.
        • Ren T.
        • Zhao H.
        • Chen S.
        • Zheng M.
        • Gao X.
        • et al.
        Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells.
        Med Oncol. 2020 Jul 28; 37: 73
        • Lai Y.
        • Xin D.
        • Bai J.
        • Mao Z.
        • Na Y.
        The important anti-apoptotic role and its regulation mechanism of PTTG1 in UV-induced apoptosis.
        J Biochem Mol Biol. 2007 Nov 30; 40: 966-972
        • Hong H.
        • Jin Z.
        • Qian T.
        • Xu X.
        • Zhu X.
        • Fei Q.
        • et al.
        Falcarindiol enhances cisplatin chemosensitivity of hepatocellular carcinoma down-regulating the STAT3-modulated PTTG1 pathway.
        Front Pharmacol. 2021 May 7; 12656697
        • Tian X.
        • Xu W.
        • Xu F.
        • Li H.
        • Anwaier A.
        • Wang H.
        • et al.
        Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response.
        Ann Med. 2022 Dec; 54: 211-226
        • Hu Z.
        • Zheng C.
        • Su H.
        • Zeng Y.
        • Lin C.
        • Guo Z.
        • et al.
        MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma.
        J Cell Biochem. 2019 Jun; 120: 9964-9978
        • Teveroni E.
        • Di Nicuolo F.
        • Bianchetti G.
        • Epstein A.
        • Grande G.
        • Maulucci G.
        • et al.
        Nuclear localization of PTTG1 promotes migration and invasion of seminoma tumor through activation of MMP-2.
        Cancers. 2021 Jan 8; 13: 212
        • Xiao Q.
        • Wei Z.
        • Li Y.
        • Zhou X.
        • Chen J.
        • Wang T.
        • et al.
        miR-186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis.
        Oncol Rep. 2018 Jun; 39: 2703-2710
        • Liang D.
        • Wu X.
        • Bai J.
        • Zhang L.
        • Yin C.
        • Zhong W.
        MiR-300 inhibits invasion and metastasis of osteosarcoma cell MG63 by negatively regulating PTTG1.
        Nan fang yi ke da xue xue bao = J Southern Med Univ. 2021 Feb 25; 41: 285-291
        • Xiea Y.
        • Wangb R.
        Pttg1 promotes growth of breast cancer through P27 nuclear exclusion.
        Cell Physiol Biochem: Int J Experimental Cell Physiol, Biochem Pharmacol. 2016; 38: 393-400
        • Repo H.
        • Gurvits N.
        • Löyttyniemi E.
        • Nykänen M.
        • Lintunen M.
        • Karra H.
        • et al.
        PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
        BMC Cancer. 2017 Oct 27; 17: 705
        • Fraune C.
        • Yehorov S.
        • Luebke A.
        • Steurer S.
        • Hube-Magg C.
        • Büscheck F.
        • et al.
        Upregulation of PTTG1 is associated with poor prognosis in prostate cancer.
        Pathol Int. 2020 Jul; 70: 441-451
        • Schmidt M.
        • Mock A.
        • Jungk C.
        • Sahm F.
        • Ull A.
        • Warta R.
        • et al.
        Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
        Oncotarget. 2016 Mar 22; 7: 14551-14568
        • Grzechowiak I.
        • Graś J.
        • Szymańska D.
        • Biernacka M.
        • Guglas K.
        • Poter P.
        • et al.
        PTTG1The oncogenic roles of and genes and pseudogene in head and neck squamous cell carcinomas.
        Diagnostics. 2020 Aug 18; : 606
        • Gong T.
        • Su X.
        • Xia Q.
        • Wang J.
        • Kan S.
        Expression of NF-κB and PTEN in osteosarcoma and its clinical significance.
        Oncol Lett. 2017 Dec; 14: 6744-6748
        • Li R.
        • Shi Y.
        • Zhao S.
        • Shi T.
        • Zhang G.
        NF-κB signaling and integrin-β1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis.
        Int J Biol Macromol. 2019 Feb 15; 123: 1035-1043
        • Tan B.
        • Yuan Z.
        • Zhang Q.
        • Xiqiang X.
        • Dong J.
        The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.
        J Appl Biomed. 2021 Dec; 19: 190-201
        • Gong Y.
        • Yang C.
        • Wei Z.
        • Liu J.
        SRPK1 promotes cell proliferation and tumor growth of osteosarcoma through activation of the NF-κB signaling pathway.
        Biol Chem. 2021 Dec 29; 403: 653-663